Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

2,357 recalls · Class II, newest first

Class II · Moderate risk

Ganirelix Acetate Injection

Failed impurities/degradation specifications: out of specification results for Ganirelix acetate acrylic acid adduct impurity.

Ongoing Impurity / degradation Lupin Pharmaceuticals Inc. NDC 70748-274-01 D-0220-2026
Class II · Moderate risk

OraVerse

Defective container: cracked/broken cartridges

Ongoing Packaging defect Novocol Pharmaceutical of Canada, Inc. NDC 0362-0101-10 D-0234-2026
Class II · Moderate risk

Cook-Walte

Defective container: cracked/broken cartridges

Ongoing Packaging defect Novocol Pharmaceutical of Canada, Inc. NDC 0362-0753-05 D-0233-2026
Class II · Moderate risk

darby dental supply

Defective container: cracked/broken cartridges

Ongoing Packaging defect Novocol Pharmaceutical of Canada, Inc. NDC 66467-9760-5 D-0231-2026
Class II · Moderate risk

3% Polocaine DENTAL

Defective container: cracked/broken cartridges

Ongoing Packaging defect Novocol Pharmaceutical of Canada, Inc. NDC 66312-441-16 D-0230-2026
Class II · Moderate risk

Nivagen

cGMP deviations

Ongoing cGMP deviation Blossom Pharmaceuticals NDC 75834-170-02 D-0209-2026
Class II · Moderate risk

Nivagen

cGMP deviations

Ongoing cGMP deviation Blossom Pharmaceuticals NDC 75834-170-01 D-0208-2026
Class II · Moderate risk

Dynashield

cGMP deviations

Ongoing cGMP deviation Blossom Pharmaceuticals NDC 67777-407-03 D-0207-2026
Class II · Moderate risk

WeCare

cGMP deviations

Ongoing cGMP deviation Blossom Pharmaceuticals NDC 67777-223-05 D-0205-2026
Class II · Moderate risk

Dynagel

cGMP deviations

Ongoing cGMP deviation Blossom Pharmaceuticals D-0204-2026
Class II · Moderate risk

Wecare Enema

cGMP deviations

Ongoing cGMP deviation Blossom Pharmaceuticals NDC 67777-402-01 D-0203-2026

Recalls by year